Beta Amyloid News and Research

RSS

Alzheimer's Association, SNMMI publish appropriate use criteria for brain amyloid imaging with PET

Only recently has it become possible to create high-quality images of the brain plaques characteristic of Alzheimer's disease in living people through positron emission tomography (PET). Even so, questions remain about what can be learned from these PET images and which people should have this test.

28 Jan 2013

New cost-effective, less invasive MRI method for diagnosis of dementia

A new way to use MRI scans may help determine whether dementia is Alzheimer's disease or another type of dementia, according to new research published in the December 26, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.

27 Dec 2012

Alzheimer's disease or FTLD can be effectively tracked using MRI

When trying to determine the root cause of a person's dementia, using an MRI can effectively and non-invasively screen patients for Alzheimer's disease or Frontotemporal Lobar Degeneration (FTLD), according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania.

27 Dec 2012

Study finds new signaling pathway involved in development of chronic inflammation of brain cells

The number of Alzheimer's patients will continue to dramatically increase in the next several decades. Various teams of researchers worldwide are feverishly investigating precisely how the illness develops. A

20 Dec 2012

Metallic probe can detect fibrils from misfolded proteins in real time

Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.

19 Dec 2012

Research provides broader understanding of processes that lead to Alzheimer's disease

Alzheimer's disease is the most common form of dementia, affecting over 35 million people worldwide. It is generally assumed that the clumping of beta-amyloid (Aβ) protein causes neuronal loss in patients.

15 Dec 2012

First U.S. patient treated with deep brain stimulation for Alzheimer's at Johns Hopkins

Researchers at Johns Hopkins Medicine in November surgically implanted a pacemaker-like device into the brain of a patient in the early stages of Alzheimer's disease, the first such operation in the United States. The device, which provides deep brain stimulation and has been used in thousands of people with Parkinson's disease, is seen as a possible means of boosting memory and reversing cognitive decline.

6 Dec 2012

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Merck, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.

3 Dec 2012

Researchers discover new gene for susceptibility to Alzheimer's disease

A large-scale international study involving French researchers from the Inserm-Institut Pasteur Lille-Universit- Lille Nord de France "Public health and molecular epidemiology of ageing-related diseases" joint research unit led by Philippe Amouyel, has just discovered a gene for susceptibility to a rare disease that causes susceptibility to a common one, Alzheimer's disease, providing evidence of the heterogeneous aetiology of Alzheimer's disease.

20 Nov 2012

For Alzheimer's, detection advances move faster than treatment options

The new brain scan technology, which went on the market in June, is spreading fast.

17 Nov 2012

Early clues regarding progression of Alzheimer's disease found in brain's metabolism

When it comes to Alzheimer's disease, scientists usually - and understandably - look to the brain as their first center of attention. Now researchers at Tel Aviv University say that early clues regarding the progression of the disease can be found in the brain's metabolism.

8 Nov 2012

In silico drug design may lead to new approach in treatment of Alzheimer's

Researchers at Dalhousie University have discovered a new technique using "computer-aided" drug design that may lead to an entirely new approach in the treatment of Alzheimer's disease (AD).

8 Nov 2012

Study identifies monoacylglycerol lipase as new therapeutic target to treat Alzheimer's

Research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, has identified an enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target to treat or prevent Alzheimer's disease.

2 Nov 2012

New data on Posiphen for Alzheimer's disease treatment to be presented at Biotech Symposium

QR Pharma, Inc., a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound "Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice" at the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA.

22 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Amarantus acquires option to license LymPro Alzheimer's diagnostic blood test from MDx

Amarantus BioSciences, Inc., a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptotis therapeutic protein MANF, today announced that it has acquired an exclusive option to license the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, LLC.

11 Oct 2012

Adult stem cells can prevent Alzheimer's disease

In the first study of its kind, researchers at Korea's leading university and the RNL Bio Stem Cell Technology Institute announced this week the results of a study that suggests an astounding possibility: adult stem cells may not only have a positive effect on those suffering from Alzheimer's disease, they can prevent the disease.

27 Sep 2012

BACE2 enzyme could represent powerful new tool against Alzheimer's

An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme - known as BACE2 - destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease.

18 Sep 2012

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.

11 Sep 2012

University of Rhode Island engineers develop new blood-testing technology

A team of engineers and students at the University of Rhode Island has developed an advanced blood-testing technology that incorporates a smartphone application, a hand-held biosensor and a credit card-sized cartridge to provide rapid, accurate biological analysis and wireless communication of test results.

7 Sep 2012